Johnson Investment Counsel Inc. increased its position in Chemed Co. (NYSE:CHE) by 5.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,503 shares of the company’s stock after buying an additional 363 shares during the period. Johnson Investment Counsel Inc.’s holdings in Chemed were worth $3,086,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. LPL Financial LLC boosted its holdings in shares of Chemed by 58.5% during the 2nd quarter. LPL Financial LLC now owns 1,839 shares of the company’s stock valued at $872,000 after purchasing an additional 679 shares during the last quarter. Bridgewater Associates LP boosted its holdings in shares of Chemed by 154.1% during the 2nd quarter. Bridgewater Associates LP now owns 15,858 shares of the company’s stock valued at $7,525,000 after purchasing an additional 9,616 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Chemed by 923.9% during the 2nd quarter. Qube Research & Technologies Ltd now owns 8,007 shares of the company’s stock valued at $3,799,000 after purchasing an additional 7,225 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Chemed by 1,700.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 54 shares of the company’s stock valued at $26,000 after purchasing an additional 51 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Chemed by 16.0% during the 2nd quarter. ProShare Advisors LLC now owns 1,780 shares of the company’s stock valued at $845,000 after purchasing an additional 246 shares during the last quarter. 87.51% of the stock is owned by institutional investors.
Separately, Royal Bank of Canada upped their target price on shares of Chemed from $604.00 to $609.00 and gave the company an “outperform” rating in a research report on Thursday, July 29th.
Shares of NYSE CHE opened at $408.46 on Thursday. Chemed Co. has a 12-month low of $403.00 and a 12-month high of $560.00. The stock has a market capitalization of $6.43 billion, a price-to-earnings ratio of 21.94, a P/E/G ratio of 3.52 and a beta of 0.45. The firm’s 50-day moving average price is $461.56 and its 200-day moving average price is $472.57.
Chemed (NYSE:CHE) last posted its quarterly earnings data on Monday, July 26th. The company reported $4.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.31. Chemed had a net margin of 14.30% and a return on equity of 35.40%. The company had revenue of $532.26 million for the quarter, compared to analyst estimates of $511.85 million. During the same period in the prior year, the company posted $4.41 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. On average, equities analysts forecast that Chemed Co. will post 17.9 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 2nd. Investors of record on Monday, August 16th were given a $0.36 dividend. This is a positive change from Chemed’s previous quarterly dividend of $0.34. This represents a $1.44 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend was Friday, August 13th. Chemed’s dividend payout ratio is 7.96%.
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Article: Death Cross
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.